DENTSPLY SIRONA (XRAY) AI Stock Analysis

• Market Cap: $2.24B
• Dividend Yield: 5.61%
• Average Volume (3M): 4.00M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.58
• Revenue Growth: -7.08%
• EPS Growth: -113.81%
• Country: US
• Employees: 14,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.37
• Shares Outstanding: 199,551,970
• 10 Day Avg. Volume: 3,607,542
• 30 Day Avg. Volume: 3,998,693
• PEG Ratio: >-0.01
• Price to Book (P/B): 1.99
• Price to Sales (P/S): 1.02
• P/FCF Ratio: 13.73
• Enterprise Value/Market Cap: 2.08
• Enterprise Value/Revenue: 1.28
• Enterprise Value/Gross Profit: 2.52
• Enterprise Value/Ebitda: -10.76
• 1Y Price Target: $13.27
• Price Target Upside: 18.38% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 16
• EPS Forecast (FY): 1.61
• Revenue Forecast (FY): $3.65B

• Rating: 46 Neutral
• Price Target: $11.00 ▼(-1.87% Downside)

DENTSPLY SIRONA's overall stock score is primarily impacted by its financial performance, which shows significant challenges across income, balance sheet, and cash flow statements. The technical analysis indicates bearish trends, and the valuation metrics are concerning with a negative P/E ratio. The earnings call sentiment is negative, highlighting strategic and operational difficulties. Despite a high dividend yield, the overall outlook remains cautious due to these pressing issues.

Positive Factors

European Sales Growth

Growth in European sales, driven by Connected Technology Solutions and Labs, indicates strong market presence and potential for expansion in Europe.

Wellspect Healthcare Growth

Wellspect Healthcare's growth across all regions suggests a robust segment that can support overall company performance and strategic goals.

SEC Investigation Conclusion

The favorable conclusion of the SEC investigation enhances the company's reputation and removes a significant overhang, allowing management to focus on strategic initiatives.

Negative Factors

Decline in Global Sales

The decline in global sales, particularly in the U.S., reflects challenges in key product lines, impacting revenue growth and market competitiveness.

Impairment Charge

The significant impairment charge indicates asset devaluation and financial strain, affecting profitability and highlighting operational inefficiencies.

Leadership Transition Challenges

Frequent leadership changes, especially in financial roles, can disrupt strategic continuity and may hinder effective financial management and turnaround efforts.

DENTSPLY SIRONA Business Overview & Revenue Model

Company Description

DENTSPLY SIRONA (XRAY) is a leading global dental products and technologies company, specializing in the development and manufacturing of a wide range of dental solutions. The company operates in various sectors, including dental consumables, dental equipment, and dental technology, with core products that include dental imaging systems, CAD/CAM systems, and restorative materials. DENTSPLY SIRONA is dedicated to improving oral health by providing innovative solutions that enhance the efficiency and effectiveness of dental practices worldwide.

How the Company Makes Money

DENTSPLY SIRONA generates revenue through multiple streams, primarily by selling dental equipment and consumables to dental professionals and clinics. Their revenue model includes direct sales of products, as well as service and support contracts for their equipment. Key revenue streams include sales of imaging systems, CAD/CAM technology, and restorative materials. The company also benefits from partnerships with dental practices and educational institutions, which help to promote their products and expand their market reach. Additionally, DENTSPLY SIRONA invests in research and development to innovate and introduce new products, thereby driving future revenue growth.

DENTSPLY SIRONA Financial Statement Overview

Summary

DENTSPLY SIRONA is experiencing significant financial challenges with declining revenue, negative profitability, increased leverage, and weakened cash flow. The company needs to address operational inefficiencies and improve financial stability to enhance its financial health.

Income Statement

DENTSPLY SIRONA has faced declining revenue and profitability, with a negative net profit margin of -25.85% in TTM. The gross profit margin remains moderate at 51.68%, but the company struggles with negative EBIT and EBITDA margins, indicating operational challenges. Revenue growth has been negative, highlighting a need for strategic improvements.

Balance Sheet

The company's debt-to-equity ratio has increased to 1.27 in TTM, indicating higher leverage. Return on equity is negative, reflecting losses. However, the equity ratio remains reasonable, suggesting some stability in asset management. The balance sheet shows potential risk due to increased debt levels.

Cash Flow

Operating cash flow is positive but has decreased, with a coverage ratio of 0.24 in TTM. Free cash flow has declined significantly, with a growth rate of -50.36%. The free cash flow to net income ratio is positive, but overall cash flow performance indicates financial strain.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.62B	3.79B	3.96B	3.92B	4.23B	3.34B
Gross Profit	1.84B	1.96B	2.09B	2.13B	2.35B	1.66B
EBITDA	-432.00M	-518.00M	249.00M	-662.00M	952.00M	330.00M
Net Income	-882.00M	-910.00M	-132.00M	-950.00M	411.00M	-73.00M
Balance Sheet
Total Assets	5.65B	5.75B	7.37B	7.64B	9.24B	9.35B
Cash, Cash Equivalents and Short-Term Investments	363.00M	272.00M	334.00M	365.00M	339.00M	438.00M
Total Debt	2.48B	2.27B	2.30B	2.15B	2.29B	2.46B
Total Liabilities	4.17B	3.81B	4.08B	3.83B	4.24B	4.42B
Stockholders Equity	1.48B	1.94B	3.29B	3.81B	5.00B	4.93B
Cash Flow
Free Cash Flow	80.00M	281.00M	228.00M	368.00M	515.00M	562.00M
Operating Cash Flow	221.00M	461.00M	377.00M	517.00M	657.00M	649.00M
Investing Cash Flow	-144.00M	-197.00M	-89.00M	-138.00M	-358.00M	-1.11B
Financing Cash Flow	-19.00M	-302.00M	-307.00M	-329.00M	-379.00M	476.00M

DENTSPLY SIRONA Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 11.21
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XRAY, the sentiment is Negative. The current price of 11.21 is below the 20-day moving average (MA) of 11.24, below the 50-day MA of 11.67, and below the 200-day MA of 13.76, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 46.33 is Neutral, neither overbought nor oversold. The STOCH value of 35.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for XRAY.

DENTSPLY SIRONA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ISRG	78 Outperform	$202.94B	75.77	16.90%	―	22.18%	21.37%
HOLX	76 Outperform	$16.72B	30.18	11.12%	―	1.74%	-25.29%
RMD	76 Outperform	$35.75B	25.07	25.41%	0.92%	9.36%	29.56%
BDX	67 Neutral	$55.73B	33.63	6.54%	2.13%	8.23%	-2.04%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
XRAY	46 Neutral	$2.24B	-2.53	-44.44%	5.61%	-7.08%	-113.81%
BAX	45 Neutral	$9.75B	-36.36	-4.70%	2.74%	-21.20%	-325.40%

DENTSPLY SIRONA Corporate Events

DENTSPLY SIRONA Appoints Interim CFO Michael Pomeroy

On November 25, 2025, DENTSPLY SIRONA Inc. announced the appointment of Michael Pomeroy as interim Chief Financial Officer. Pomeroy, with extensive experience in finance leadership across various industries, will support the company’s President and CEO, Daniel T. Scavilla, until a permanent CFO is appointed. This strategic appointment aims to leverage Pomeroy’s expertise in growth, turnaround, and operational improvement to strengthen the company’s financial leadership during the transition period.

DENTSPLY SIRONA CFO Matthew Garth Steps Down

On October 31, 2025, DENTSPLY SIRONA Inc. announced that Matthew E. Garth will step down from his role as Executive Vice President and Chief Financial Officer, effective November 5, 2025. The company has begun searching for a new CFO and clarified that Garth’s departure is not due to any disagreements regarding the company’s financial practices. Concurrently, Daniel T. Scavilla, the company’s President and CEO, will take on the additional role of interim principal financial officer. This transition is not expected to involve any new compensatory arrangements for Scavilla.

DENTSPLY SIRONA SEC Investigation Concludes Favorably

On October 14, 2025, DENTSPLY SIRONA announced that the SEC has concluded its investigation, which began in May 2022, into the company’s financial reporting matters without recommending any enforcement action. This closure is seen as a significant and favorable development for the company, reflecting its cooperation with the SEC and potentially strengthening its position in the industry.

DENTSPLY SIRONA Announces Leadership Transition for Rosenzweig

On October 2, 2025, DENTSPLY SIRONA announced that Richard C. Rosenzweig will transition from his role as Executive Vice President, Corporate Development, General Counsel, and Secretary to a non-executive position as Special Legal Advisor, effective October 3, 2025. This transition is part of a mutual agreement, and Mr. Rosenzweig will continue to serve in an advisory capacity until March 4, 2026, with a monthly fee and additional severance benefits, before becoming an independent contractor consultant for a year.

DENTSPLY SIRONA Approves Retention Award for Executives

On September 19, 2025, DENTSPLY SIRONA‘s Board approved a one-time retention equity incentive award for executives, including Tony Johnson, to recognize his performance during a leadership transition. The award, valued at $2 million in stock options, aims to retain Johnson for three years, with options vesting on the third anniversary and expiring ten years from the grant date.